Abbott Laboratories stock (US0028241000): shares edge higher ahead of Q2 2026 earnings after guidance update
02.06.2026 - 23:05:48 | ad-hoc-news.de
Abbott Laboratories shares in the United States continued to see active trading at the beginning of June 2026, with the NYSE-listed stock changing hands above USD 85 as investors digest the company’s latest full-year 2026 and Q2 2026 earnings guidance and look ahead to the next set of quarterly results, according to data from the New York Stock Exchange as of 06/01/2026.
The stock, which trades under the ticker ABT on the NYSE, has been fluctuating after a period of share price weakness over the past year, with some market commentary highlighting that the company’s market capitalization has declined by more than 20% on a one-year view as of late March 2026, based on figures compiled by Stock Analysis as of 03/30/2026.
According to a recent note cited by MarketBeat on 06/02/2026, Abbott Laboratories has issued full-year 2026 earnings guidance in a range of USD 5.38 to USD 5.58 per share and Q2 2026 earnings guidance of USD 1.25 to USD 1.31 per share, setting reference points for analysts and investors ahead of the next earnings release.
This guidance range, reported for the United States-based medical devices and diagnostics group, provides the key benchmark for how the market will assess the upcoming quarterly results when they are released via Abbott’s investor relations channel and regulatory filings with the U.S. Securities and Exchange Commission.
The company is a constituent of the large-cap U.S. healthcare universe, and its NYSE listing underpins its visibility among investors following the S&P 500 and other major U.S. equity indices, even as the stock has faced valuation pressure over the past year.
While trading is centered on the U.S. market, the stock is also available to German investors through off-exchange venues such as Tradegate, where it is quoted in euros, providing an additional access point for European retail investors seeking exposure to the U.S. healthcare sector alongside the primary NYSE listing.
The stock traded at around the high-80s in USD terms on 06/01/2026 on the NYSE, according to price data referenced by StockInvest and other market sources for the latest session, illustrating modest day-to-day volatility as investors await the Q2 2026 print.
As of: 06/02/2026
By the editorial team - specialized in equity coverage.
At a glance
- Name: Abbott Laboratories
- Sector/industry: Healthcare equipment, diagnostics and medical devices
- Headquarters/country: Abbott Park, United States
- Core markets: North America, Europe, Asia-Pacific and emerging markets
- Key revenue drivers: Medical devices, diagnostics systems, established pharmaceuticals and nutritional products
- Home exchange/listing venue: New York Stock Exchange (ABT)
- Trading currency: USD
Abbott Laboratories: core business model
Abbott Laboratories focuses on supplying medical devices, diagnostic platforms, branded generic medicines and nutrition products globally, with growth heavily influenced by demand for cardiovascular devices, diabetes care systems, laboratory diagnostics and consumer nutrition categories.
Latest quarterly results for Abbott Laboratories at a glance
For context around the newly reaffirmed guidance, investors are still anchored on the company’s most recently reported quarterly performance for the United States market, where Abbott has detailed revenue and earnings trends across its four main segments, including medical devices and diagnostics, in its latest earnings release and accompanying SEC filings.
That most recent quarter showed continued contributions from areas such as cardiovascular and diabetes care devices, as well as core laboratory diagnostics and nutritional products, and it serves as the base from which the company set its 2026 earnings per share guidance in the USD 5.38 to USD 5.58 range and Q2 2026 EPS guidance of USD 1.25 to USD 1.31, figures that will be scrutinized closely when the next quarterly report is published through Abbott’s investor relations website and U.S. regulatory channels.
Read more
Additional news and developments on the stock can be explored via the linked overview pages.
Sentiment and reactions on Abbott Laboratories
Market participants are debating how Abbott Laboratories’ 2026 earnings guidance and upcoming Q2 2026 results could influence the share price path after a year of weaker performance.
Conclusion
Abbott Laboratories enters June 2026 trading on the NYSE with investors focused on the company’s stated earnings per share guidance ranges for full-year 2026 and Q2 2026 and how those figures will stack up against the next quarterly report.
The latest reported quarterly results and segment trends provide the backdrop for this guidance and will shape market expectations as the United States-based healthcare group prepares to publish its Q2 2026 numbers via its investor relations channel and U.S. regulatory filings.
Given the share price pullback and market cap decline over the past year, the forthcoming earnings update is likely to be a key reference point for how the stock is valued within the broader U.S. healthcare sector.
Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.
